News, insight, and analysis from industry experts to help benefits brokers, consultants and advisors make their way through the tumultuous reformed health care marketplace. Content will help them grow their practices by focusing on a wide range of products, discussing new sales and marketing strategies and highlighting innovative and disruptive brokers who are forging a new path in today's benefits marketplace.
Federal health experts are recommending that use of Merck's blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.
